Bevacizumab: Zankapfel der Glioblastomtherapie

Thomas Hundsberger; Michael Weller

doi:10.1024/1661-8157/a002650

Bevacizumab: Zankapfel der Glioblastomtherapie

Praxis (Bern 1994). 2017 Apr;106(8):415-420. doi: 10.1024/1661-8157/a002650.

[Article in German]

Authors

Thomas Hundsberger^{1

2}, Michael Weller³

Affiliations

¹ 1 Klinik für Neurologie, Kantonsspital St. Gallen.
² 2 Klinik für Hämatologie und Onkologie, Kantonsspital St. Gallen.
³ 3 Klinik für Neurologie, Universitätsspital Zürich.

PMID: 28401779
DOI: 10.1024/1661-8157/a002650

No abstract available

Keywords: Bevacizumab; Glioblastom; Glioblastoma; Glioblastome; bevacizumab; facteur de croissance endothélial vasculaire; vascular endothelial growth factor; vaskulärer endothelialer Wachstumsfaktor.

Publication types

Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bevacizumab / adverse effects
Bevacizumab / therapeutic use*
Brain Neoplasms / drug therapy*
Brain Neoplasms / mortality
Chemoradiotherapy, Adjuvant
Clinical Trials, Phase II as Topic
Combined Modality Therapy
Disease-Free Survival
Glioblastoma / drug therapy*
Glioblastoma / mortality
Humans
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Recurrence, Local / mortality

Substances

Bevacizumab